Simon Newman

Part of Tonix Pharmaceuticals Holding Corp., Healion Bio, Inc. is a biotechnology development company based in Frederick, MD. The company is focused on developing the next generation of antiviral compounds, with two antiviral platforms: the HB-100 series of protease inhibitors and the HB-200/300 series of next-generation antiviral biologics. The HB-100 series is a first-in-class antiviral with an orthogonal mechanism of action to existing drugs. The company was founded by Sina Bavari and Simon Newman, with Simon Newman serving as CEO since incorporation. Healion Bio was acquired by Tonix Pharmaceuticals Holding Corp. on February 01, 2023 for $1.20 million.